Basel, 5 March 2013
Roche Annual General Meeting 2013
26th dividend increase in succession – election/re-election of all members of the Board of Directors nominated
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that its Ordinary Annual General Meeting voted in favour of all the Board of Directors’ proposals. The 748 shareholders in attendance, representing 88.8% of the total of 160,000,000 shares, approved the Annual Report, the financial statements and the consolidated financial statements for 2012. Furthermore, they decided to increase the dividend for the past financial year by 8% to 7.35 Swiss francs (gross) per share and non-voting equity security. This is the 26th dividend increase in succession.
In a consultative vote, the shareholders acknowledged and accepted the 2012 Remuneration Report by 99.6% of the votes represented.
The following were re-elected for the statutory term of office of two years: Dr Andreas Oeri, Prof. Dr Pius Baschera, Paul Bulcke, William M. Burns, Dr Christoph Franz, Dame DeAnne Julius, Dr Arthur D. Levinson, Peter R. Voser and Prof. Dr Beatrice Weder di Mauro. Dr Severin Schwan was newly elected to the Board, also for a term of office of two years.
Franz B. Humer, Chairman of the Roche Board of Directors, informed today’s AGM that he will not stand for re-election to the Board in 2014. Roche will nominate a successor for the chairmanship in autumn 2013.
Roche Chairman Franz B. Humer: “Roche posted an outstanding result in 2012 in a challenging and increasingly cost-sensitive market environment. This success is also reflected in the dividend payout, which once again is high. More than half the company’s profit is distributed to its shareholders. I am looking forward to the next 12 months, and I intend to perform my duties as Chairman with enthusiasm and drive.”
Severin Schwan, Roche Group CEO, commented: “I am pleased that I have been elected to the Board of Directors and would like to thank our shareholders for this vote of confidence. Roche – the world’s largest biotechnology company – is well positioned for the future. By developing specific and effective therapies, we offer significant added value for the healthcare system at a time when it faces growing cost pressures. With our breast cancer drug Kadcyla, which recently received FDA approval, we provide both physicians and patients a highly effective treatment with relatively few side effects that marks a milestone in cancer therapy.”
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, infectious diseases, inflammation, metabolism and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2012 Roche had over 82,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 45.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information please visit www.roche.com.
All trademarks used or mentioned are protected by law.